|
Market Report
|
 Pricing and Reimbursement in Oncology - Do payers believe oncology drugs offer good value?
The oncology market has shown remarkable growth in recent years, driven by the advent of targeted therapy and the high level of unmet needs in the disease, and it is poised for further expansion. While this will provide companies with opportunities, a key hurdle for novel cancer drugs will be the increasing pharmacoeconomic vigilance that prevails within cash-strapped healthcare systems.
|
|
Read more...
|
|
|
Market Report
|
Obesity - Lack of Reimbursement Limits Market Potential
Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped.
|
|
Read more...
|
|
|
Market Report
|
Therapeutic Cancer Vaccines - A turbulent path from bench to bedside
Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open.
|
|
Read more...
|
|
|
Market Report
|
Antibacterials - Growth in resistance rates drives niche indications
The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizer's Zithromax) in 2005.
|
|
Read more...
|
|
|
Market Report
|
Prescribing trends indicate that neurologists are not adhering to guidelines
A lack of prescriber adherence to both marketing licenses and pharmacoeconomic guidelines represents both a challenge and opportunity for pharmaceutical companies marketing current Alzheimer's disease drugs. Indication expansion between disease severities may not be a viable commercial option; conversely, stricter guidelines by bodies such as the UK's NICE will not necessarily threaten the market.
|
|
Read more...
|
|
|
Market Report
|
With increasing regulatory clarity and high revenue potential, interest in biosimilars increases
With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.
|
|
Read more...
|
|
|
Company Report
|
Web-assisted relationship- and community-building for the pharmaceutical industry
CRM is a business strategy by which a company seeks to maximize the value of its products by managing the customer relationship, with specific aims to boost customer retention and increase market share, while reducing the costs of sales, marketing and customer fulfillment. CRM is made necessary because of advances in Web-enabled technologies, which have changed the dynamics of sales and marketing.
|
|
Read more...
|
|
|
Market Report
|
Atherosclerosis - HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment
Atherosclerosis generally begins in childhood and manifests clinically in mid-to-late adulthood. While the mortality from atherosclerotic conditions has declined significantly, in developed countries cardiovascular disease accounts for nearly 50% of all deaths, and within the next 15-20 years, is projected to surpass infectious diseases to become the leading cause of death worldwide.
|
|
Read more...
|
|
|
Market Report
|
Melanoma - Lucrative commercial opportunities persist
Melanoma comprises just 5% of all skin cancers but it is the most deadly. In 2006, more than 100,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.
|
|
Read more...
|
|
|
Market Report
|
Respiratory Syncytial Virus (RSV) - A market yet to reach its full potential
RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly people, patients with underlying pulmonary or cardiac disease, premature infants, children under four years old and immunocompromised patients.
|
|
Read more...
|
|
|
Market Report
|
Multiple Sclerosis - Disease-modifying efficacy and side effects guide treatment choice
The disease-modifying drugs are considered by physicians to represent a significant advance for the management of MS. However, none is fully effective and there are problems with regards to side effects, dosing regimens and cost. Tysabri, a novel once-monthly drug is expected to be an improvement in terms of efficacy; however, there remains a concern over side effects and long-term safety.
|
|
Read more...
|
|
|
Market Report
|
Osteoarthritis - Market sees steady growth
The 2004 withdrawal of Vioxx from the global market had a negative effect on the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in 2005. However, as patients sought an alternative to the COX-2s, there was positive growth in traditional NSAIDs, non-narcotic analgesics, narcotic analgesics, corticosteroids and HA viscosupplements, leading to a 1.1% increase in total market value.
|
|
Read more...
|
|
|
Market Report
|
Psoriasis - Anti-TNF's lead another indication
There is no cure for psoriasis, which profoundly affects sufferers quality of life, physical and social functioning. There is a particular unmet need for effective long-term therapies for psoriasis. Prevalence is the highest of the autoimmune diseases at 16 million in 2006, but this is deceptive in terms of market size, as the treated and severe patient populations are comparatively small.
|
|
Read more...
|
|
|
Market Report
|
What companies need to know about trends in physicians and consumers' use of the Internet
An understanding of the present and future market trends surrounding eHealth is vital in order for the pharmaceutical industry to develop effective multi-channel marketing strategies. It is advisable for stakeholders to invest in targeted initiatives that meet the specific information needs and support the decision making processes of the large numbers of physician and consumer groups online.
|
|
Read more...
|
|
|
Market Report
|
Key trends and strategic issues shaping the industry
Datamonitor has identified the key trends and events that impacted the pharmaceutical market on a macro-environmental and corporate strategy level in 2006. These range from the continuation of long term trends such as the focus on cost containment to more recent impacts such as the effects of Medicare Part D and the increasing power of the Democratic part in the US.
|
|
Read more...
|
|
|
Market Report
|
Esophageal Cancer: Treatment paradigms need revolution not evolution
Globally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates widely depending on geographical area. While relatively uncommon in Western countries, 50% of patients still present with locally advanced unresectable or distant metastatic disease, where treatment is complicated and chances of a cure are reduced.
|
|
Read more...
|
|
|
Market Report
|
Small Cell Lung Cancer and Malignant Mesothelioma
SCLC accounts for one-fifth of all lung tumor types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
|
|
Read more...
|
|
|
Market Report
|
Search Engine Marketing, insights and trends for pharmaceutical industry
At the recent e-Marketing Summit in Zürich, organised by Eyeforpharma we have had pleasue to participate at workshop "Search Engine Marketing, insights and trends in Pharma".
|
|
Read more...
|
|
Farmavita.Net Journal 
